Bruker Spatial Biology v. 10X Genomics: Dismissed With Prejudice After 936 Days
Bruker Spatial Biology, Inc. brought a patent infringement action against 10X Genomics, Inc. in the District of Delaware, asserting two patents covering chemical compositions used in spatial biology workflows. After 936 days of litigation, both parties jointly stipulated to dismiss all claims and counterclaims with prejudice, each bearing its own costs.
Spatial Biology IP Clash Ends in Binding Mutual Walk-Away
Filed on 20 October 2022 in the District of Delaware before Judge Matthew F. Kennelly, this infringement action pitted Bruker Spatial Biology, Inc. against 10X Genomics, Inc. — two of the dominant commercial players in spatial transcriptomics. Bruker asserted two United States patents, US11473142B2 and US11377689B2, both directed to chemical compositions and their uses, technologies foundational to spatially resolved gene-expression platforms.
The case closed on 13 May 2025 through a Fed. R. Civ. P. 41(a)(1)(A)(ii) stipulated dismissal with prejudice. Crucially, the order extinguishes all claims and counterclaims asserted by either side and contains an explicit mutual cost-bearing provision, meaning neither party extracted a fee award. A with-prejudice dismissal operates as a final adjudication on the merits, permanently barring Bruker from reasserting the same patent claims against 10X Genomics on the same accused products.
A 936-day lifespan suggests substantive litigation activity — claim construction, possibly discovery — before the parties reached their resolution, consistent with a negotiated commercial settlement rather than an early procedural exit. The absence of any public settlement terms or licensing disclosure is typical for spatial biology disputes where competitive commercial terms are highly sensitive. What drove the ultimate agreement — cross-licensing, design-around, or pure commercial calculus — remains undisclosed on the public record.
Filing to Dismissed with Prejudice in 936 days
936 days — approximately 2.5 years, longer than the median D. Del. patent case to dismissal
Dismissed with prejudice: what the stipulated exit means for both parties
Rule 41(a)(1)(A)(ii): A Binding Stipulated Dismissal
A Fed. R. Civ. P. 41(a)(1)(A)(ii) dismissal requires the signed agreement of all parties who have appeared. Unlike a unilateral voluntary dismissal, it cannot be taken back. The ‘with prejudice’ designation elevates it to a final adjudication on the merits, closing the courthouse door permanently on the specific claims asserted. Neither party can later argue the case was dismissed on procedural rather than substantive grounds.
Final — no re-filing permittedBruker Permanently Relinquishes These Patent Claims Against 10X
By agreeing to a with-prejudice dismissal, Bruker Spatial Biology surrenders the right to assert US11473142B2 and US11377689B2 against 10X Genomics on the accused products in this action. The patents themselves remain in force and enforceable against third parties. Whether Bruker secured any commercial concession — such as a cross-licence, royalty arrangement, or market-access agreement — is not disclosed in the public record.
Patents survive; this suit cannot be re-filed10X Genomics Achieves Permanent Freedom From These Specific Claims
10X Genomics obtains a preclusive shield: Bruker cannot reassert the same claims from these two patents in a new action based on the same accused conduct. The mutual cost-bearing provision means 10X absorbed its own substantial litigation spend without recovery. The counterclaims 10X filed — likely invalidity and/or non-infringement — are also dismissed with prejudice, removing any cloud those counterclaims might have created over Bruker’s patent title.
Claim preclusion applies to 10XSpatial Biology IP Rivalry Continues Beyond This Docket
Bruker and 10X Genomics compete directly in high-growth spatial transcriptomics markets. A mutual dismissal after 936 days, with no public winner declared, typically signals a negotiated equilibrium — often a cross-licence or go-forward coexistence agreement. Both companies hold deep patent portfolios in this space, suggesting parallel or successor disputes remain possible on different patent families or newly accused products.
Competitive rivalry ongoingFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Bruker Spatial Biology, Inc. | Company | Spatial biology technology company — holder of US11473142B2 and US11377689B2Search in Eureka ↗ |
| Defendant | 10X Genomics, Inc. | Company | 10X Genomics, Inc. — leading spatial transcriptomics and single-cell genomics platform providerSearch in Eureka ↗ |
| Plaintiff counsel | Brian E. Farnan | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine E. Lehman | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Concord Cheung | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Courtland L. Reichman | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Derek C. Walter | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Edward R. Reines | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Karnik F. Hajjar | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael J. Farnan | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Sarah O. Jorgensen | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Savannah H. Carnes | Attorney | Counsel for Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Farnan LLP | Law Firm | Representing Bruker Spatial Biology, Inc.Search in Eureka ↗ |
| Defendant counsel | Alexandra M. Ewing | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Defendant counsel | Frederick L. Cottrell , III | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Defendant counsel | Grace Gretes | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Defendant counsel | Jason James Rawnsley | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Defendant counsel | Joanna Schacter | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Defendant counsel | Kiley White | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Defendant counsel | Li Shen | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Defendant counsel | Matthew D. Powers | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Defendant counsel | Paul T. Ehrlich | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Defendant counsel | Robert L. Gerrity | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Defendant counsel | Ronald J. Pabis | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Defendant counsel | Samantha A. Jameson | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Defendant counsel | Stefani C. Smith | Attorney | Counsel for 10X Genomics, Inc.Search in Eureka ↗ |
| Defendant law firm | Richards Layton & Finger PA | Law Firm | Representing 10X Genomics, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Matthew F. Kennelly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation explicitly invokes Rule 41(a)(1)(A)(ii), requiring mutual consent, and designates the dismissal as ‘with prejudice’ — language that carries full res judicata effect. By including all claims and counterclaims in the same instrument and imposing a symmetric cost-bearing provision, the parties structured an exit that confers no judicial admission of infringement or invalidity on either side. The phrasing is neutral by design, preserving each party’s public litigation posture while achieving a binding commercial endpoint.
US11473142B2 & US11377689B2 — Chemical Compositions for Spatial Biology
US11473142B2 (application US17/476712) and US11377689B2 (application US17/476707) are United States utility patents held by Bruker Spatial Biology, Inc., directed to chemical compositions and their uses — a foundational claim category in spatial biology. The closely related application numbers suggest a deliberate continuation or divisional filing strategy, likely designed to secure broad and layered claim coverage across composition-of-matter and method-of-use dimensions within the same underlying technology platform.
In the spatial transcriptomics sector, chemical composition patents covering probe chemistries, hybridisation reagents, or capture molecules carry substantial commercial leverage because they sit upstream of entire assay workflows. Competitors building spatial genomics platforms cannot easily design around composition claims without reformulating core reagent systems. For Bruker — which competes directly with 10X Genomics in this high-growth segment — these patents represent both defensive portfolio assets and potential licensing revenue streams against third-party platform developers.
Should you run an FTO against US11473142B2 and US11377689B2?
Any company developing, manufacturing, or commercialising chemical compositions used in spatial transcriptomics, in situ sequencing, or related spatially resolved genomics workflows should treat these two Bruker patents as priority FTO targets. The with-prejudice dismissal in this case does not narrow or invalidate the claims — it merely resolves Bruker’s dispute with 10X Genomics. Emerging spatial biology platforms, reagent kit suppliers, and contract research organisations working in this space remain fully exposed.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map product workflows against the claim trees of US11473142B2 and US11377689B2, identify claim elements present in competing product lines, surface related continuation or divisional applications in Bruker’s portfolio, and benchmark prosecution history for potential prosecution history estoppel arguments — all in a fraction of the time required by manual analysis.
Run a freedom-to-operate analysis on US11473142B2 to assess your product’s exposure
Run FTO in Eureka →Similar Patent Cases: Chemical Composition Patents in Spatial Biology
Cases involving chemical composition and spatial transcriptomics patent assertions in the District of Delaware, including related Bruker and 10X Genomics IP disputes.
What this case signals for the spatial biology IP landscape
Bruker vs. 10X is a bellwether for how chemical-composition patents are enforced in the rapidly consolidating spatial transcriptomics sector.
With-prejudice dismissals after extended litigation typically signal settlement
A 936-day case that ends in a mutual Rule 41 stipulation — rather than a court ruling — is strongly consistent with a confidential commercial resolution. IP teams watching spatial biology disputes should treat this as a signal that both Bruker and 10X now likely operate under some form of bilateral IP agreement, even if its terms are undisclosed.
The asserted patents remain live weapons against all other market participants
US11473142B2 and US11377689B2 are not invalidated or narrowed by this outcome. Any competitor other than 10X Genomics — including emerging spatial biology platforms — remains fully exposed to assertion of these patents. Companies building on chemical composition workflows used in spatial transcriptomics should conduct or update their FTO analysis against both patents promptly.
Bruker v 10X — key questions answered
A with-prejudice dismissal under Rule 41(a)(1)(A)(ii) operates as a final adjudication on the merits. Bruker Spatial Biology cannot re-file the same patent infringement claims based on US11473142B2 and US11377689B2 against 10X Genomics for the same accused conduct. The patents themselves remain valid and enforceable against other parties.
Yes. The dismissal resolves only the dispute between Bruker and 10X Genomics. It does not adjudicate validity or infringement on the merits. Both patents remain in force and can be asserted against any other party in the spatial biology or chemical composition space that has not obtained a licence or similar protection.
A 936-day timeline before a stipulated dismissal typically suggests the parties engaged in substantive litigation activity — potentially including claim construction proceedings and discovery — before reaching a negotiated resolution. Early-stage settlements in D. Del. patent cases tend to resolve within 12–18 months; a 2.5-year duration is consistent with complex technical disputes where commercial negotiations ran in parallel to active litigation.
The stipulation specifies that each party bears its own costs, expenses, and attorneys’ fees. This means neither side sought or obtained fee-shifting under 35 U.S.C. § 285 (exceptional case doctrine). The symmetric arrangement is commercially neutral and avoids creating any public record of one party having behaved improperly, which is consistent with a negotiated resolution between ongoing commercial competitors.
The public record does not detail the specific counterclaims 10X Genomics asserted, but in patent infringement actions it is standard for defendants to counterclaim for declarations of non-infringement and invalidity. The stipulation dismissed all counterclaims with prejudice, which means 10X cannot pursue those invalidity or non-infringement positions against the asserted patents in future proceedings arising from the same accused conduct.
PatSnap Eureka searches patents and litigation data to answer instantly.